The role of chemotherapy for metastatic breast cancer

Kathy Miller, G. W. Sledge

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Metastatic breast cancer remains a devastating and largely incurable disease. Currently available therapies offer meaningful palliation for many and modest prolongation of survival for some patients. Singleagent hormonal therapy remains the treatment of choice for patients with ER-positive disease, with sequential use of further hormonal agents or cytotoxic chemotherapy at the time of disease progression. Chemotherapy is appropriate as initial therapy for patients with receptor-negative or rapidly progressive visceral disease. Although combination regimens may increase response rates, the lack of survival benefit does not justify the increased toxicity of aggressive combination regimens in most patients. Maintenance chemotherapy deserves consideration in selected well-informed patients, especially those with few therapy-related side effects. High-dose regimens confer substantial toxicity with no cleat therapeutic advantage and cannot be recommended outside of ongoing trials. New chemotherapy agents offer the hope of effective salvage therapy with acceptable toxicity a larger number of patients. Perhaps most promising, the development of targeted, biologically based therapies such as rhuMAbHER2 offers encouragement for the future.

Original languageEnglish
Pages (from-to)415-434
Number of pages20
JournalHematology/Oncology Clinics of North America
Volume13
Issue number2
DOIs
StatePublished - 1999

Fingerprint

Breast Neoplasms
Drug Therapy
Therapeutics
Maintenance Chemotherapy
Salvage Therapy
Cytotoxins
Disease Progression
Survival Rate
Survival

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

The role of chemotherapy for metastatic breast cancer. / Miller, Kathy; Sledge, G. W.

In: Hematology/Oncology Clinics of North America, Vol. 13, No. 2, 1999, p. 415-434.

Research output: Contribution to journalArticle

@article{5e6faa4615514414883a28d0aba9a137,
title = "The role of chemotherapy for metastatic breast cancer",
abstract = "Metastatic breast cancer remains a devastating and largely incurable disease. Currently available therapies offer meaningful palliation for many and modest prolongation of survival for some patients. Singleagent hormonal therapy remains the treatment of choice for patients with ER-positive disease, with sequential use of further hormonal agents or cytotoxic chemotherapy at the time of disease progression. Chemotherapy is appropriate as initial therapy for patients with receptor-negative or rapidly progressive visceral disease. Although combination regimens may increase response rates, the lack of survival benefit does not justify the increased toxicity of aggressive combination regimens in most patients. Maintenance chemotherapy deserves consideration in selected well-informed patients, especially those with few therapy-related side effects. High-dose regimens confer substantial toxicity with no cleat therapeutic advantage and cannot be recommended outside of ongoing trials. New chemotherapy agents offer the hope of effective salvage therapy with acceptable toxicity a larger number of patients. Perhaps most promising, the development of targeted, biologically based therapies such as rhuMAbHER2 offers encouragement for the future.",
author = "Kathy Miller and Sledge, {G. W.}",
year = "1999",
doi = "10.1016/S0889-8588(05)70063-0",
language = "English",
volume = "13",
pages = "415--434",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - The role of chemotherapy for metastatic breast cancer

AU - Miller, Kathy

AU - Sledge, G. W.

PY - 1999

Y1 - 1999

N2 - Metastatic breast cancer remains a devastating and largely incurable disease. Currently available therapies offer meaningful palliation for many and modest prolongation of survival for some patients. Singleagent hormonal therapy remains the treatment of choice for patients with ER-positive disease, with sequential use of further hormonal agents or cytotoxic chemotherapy at the time of disease progression. Chemotherapy is appropriate as initial therapy for patients with receptor-negative or rapidly progressive visceral disease. Although combination regimens may increase response rates, the lack of survival benefit does not justify the increased toxicity of aggressive combination regimens in most patients. Maintenance chemotherapy deserves consideration in selected well-informed patients, especially those with few therapy-related side effects. High-dose regimens confer substantial toxicity with no cleat therapeutic advantage and cannot be recommended outside of ongoing trials. New chemotherapy agents offer the hope of effective salvage therapy with acceptable toxicity a larger number of patients. Perhaps most promising, the development of targeted, biologically based therapies such as rhuMAbHER2 offers encouragement for the future.

AB - Metastatic breast cancer remains a devastating and largely incurable disease. Currently available therapies offer meaningful palliation for many and modest prolongation of survival for some patients. Singleagent hormonal therapy remains the treatment of choice for patients with ER-positive disease, with sequential use of further hormonal agents or cytotoxic chemotherapy at the time of disease progression. Chemotherapy is appropriate as initial therapy for patients with receptor-negative or rapidly progressive visceral disease. Although combination regimens may increase response rates, the lack of survival benefit does not justify the increased toxicity of aggressive combination regimens in most patients. Maintenance chemotherapy deserves consideration in selected well-informed patients, especially those with few therapy-related side effects. High-dose regimens confer substantial toxicity with no cleat therapeutic advantage and cannot be recommended outside of ongoing trials. New chemotherapy agents offer the hope of effective salvage therapy with acceptable toxicity a larger number of patients. Perhaps most promising, the development of targeted, biologically based therapies such as rhuMAbHER2 offers encouragement for the future.

UR - http://www.scopus.com/inward/record.url?scp=0033031141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033031141&partnerID=8YFLogxK

U2 - 10.1016/S0889-8588(05)70063-0

DO - 10.1016/S0889-8588(05)70063-0

M3 - Article

VL - 13

SP - 415

EP - 434

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 2

ER -